ArticleMolecular cancer therapeutics2017

The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.

Hui Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.